Annals of Surgical Oncology

, Volume 14, Issue 2, pp 424–431 | Cite as

Neoadjuvant Chemoradiation Versus Hyperfractionated Accelerated Radiotherapy in Locally Advanced Rectal Cancer

  • Wim Ceelen
  • Tom Boterberg
  • Piet Pattyn
  • Marc van Eijkeren
  • Jean-Marc Gillardin
  • Pieter Demetter
  • Peter Smeets
  • Nancy Van Damme
  • Els Monsaert
  • Marc Peeters



Neoadjuvant therapy is increasingly used in resectable locally advanced rectal cancer. The exact role of the addition of chemotherapy is not established. We compared neoadjuvant therapy using chemoradiation (CRT) or hyperfractionated accelerated radiotherapy (HART).


Clinical, pathological, and survival data were obtained from patients with resectable stage II or III rectal cancer within 7 cm from the anal verge. A group of 50 patients was treated with a preoperative dose of 41.6 Gy of radiotherapy (RT) in two daily fractions of 1.6 Gy over 13 days immediately followed by surgery (HART). A second group of 96 patients received 45 Gy of conventionally fractionated RT in 25 daily fractions of 1.8 Gy combined with 5-fluorouracil–based chemotherapy followed by surgery within 4 to 6 weeks (CRT). Both groups were compared in terms of morbidity, pathological downstaging, local recurrence, and survival.


Both groups were comparable in terms of preoperative clinicopathological variables. The mean distance from the anal verge was 5.8 cm (HART) versus 4.9 cm (CRT). Sphincter preservation was possible in 74% (HART) versus 83.5% (CRT) of patients (P = .013). The clinical anastomotic leak rate was 2% (HART) versus 2.2% (CRT). Pathological complete response was observed in 4% (HART) versus 18% (CRT) of the resected specimens (P = .002). A pelvic recurrence developed in 6% (HART) versus 4.4% (CRT) of patients (P = .98). Overall 5-year survival was 58% (HART) versus 66% (CRT) (P = .19); disease-free 5-year survival was 51% (HART) versus 62% (CRT) (P = .037).


Compared with preoperative HART followed by immediate surgery, preoperative CRT followed by a 6-week waiting period enhances pathological response and increases sphincter preservation rate. This could be explained by the addition of chemotherapy or the longer interval between neoadjuvant therapy and surgery. No statistically significant difference was observed in local control or overall survival.


Rectal cancer Neoadjuvant Total mesorectal excision Hyperfractionated accelerated therapy Chemoradiation 


  1. 1.
    Glimelius B, Pahlman L. Preoperative or postoperative radiotherapy in rectal-carcinoma—a randomized multicenter trial. Lyon Chir 1991; 87:3–8Google Scholar
  2. 2.
    Gray R, Hills R, Stowe R, et al. Adjuvant radiotherapy for rectal cancer: a systematic overview of 8507 patients from 22 randomised trials. Lancet 2001; 358:1291–304CrossRefGoogle Scholar
  3. 3.
    Heald RJ, Husband EM, Ryall RDH. The mesorectum in rectal-cancer surgery—the clue to pelvic recurrence. Br J Surg 1982; 69:613–6PubMedCrossRefGoogle Scholar
  4. 4.
    Enker WE, Thaler HT, Cranor ML, et al. Total mesorectal excision in the operative treatment of carcinoma of the rectum. J Am Coll Surg 1995; 181:335–46PubMedGoogle Scholar
  5. 5.
    Enker WE. Total mesorectal excision—the new golden standard of surgery for rectal cancer. Ann Med 1997; 29:127–33PubMedGoogle Scholar
  6. 6.
    Ceelen W, Pattyn P. Total mesorectal excision in the treatment of rectal cancer: a review. Acta Chir Belg 2000; 100:94–9PubMedGoogle Scholar
  7. 7.
    Kapiteijn E, Marijnen CAM, Nagtegaal ID, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 2001; 345:638–46PubMedCrossRefGoogle Scholar
  8. 8.
    Minsky BD, Cohen AM, Enker WE, et al. Preoperative 5-FU, low-dose leucovorin, and radiation therapy for locally advanced and unresectable rectal cancer. Int J Radiat Oncol 1997; 37:289–95CrossRefGoogle Scholar
  9. 9.
    Bosset JF, Magnin V, Maingon P, et al. Preoperative radiochemotherapy in rectal cancer: long-term results of a phase II trial. Int J Radiat Oncol 2000; 46:323–7CrossRefGoogle Scholar
  10. 10.
    Gambacorta MA, Valentini V, Morganti AG, et al. Chemoradiation with raltitrexed (Tomudex) in preoperative treatment of stage II–III resectable rectal cancer: a phase II study. Int J Radiat Oncol 2004; 60:130–8CrossRefGoogle Scholar
  11. 11.
    Hall EJ. Physical and biological basis of radiation therapy. In: Cox JD, Kian Ang K, eds. Radiation Oncology: Rationale, Technique, Results. St Louis: Mosby, 2003; 3–62Google Scholar
  12. 12.
    Horiot JC, Lefur R, Nguyen T, et al. Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma—final analysis of a randomized trial of the EORTC Cooperative Group of Radiotherapy. Radiother Oncol 1992; 25:231–41PubMedCrossRefGoogle Scholar
  13. 13.
    Shimomatsuya T, Tanigawa N, Muraoka R. Proliferative activity of human tumors—assessment using bromodeoxyuridine and flow-cytometry. Jpn J Cancer Res 1991; 82:357–62PubMedGoogle Scholar
  14. 14.
    Cutress RI, Mullee MA, Rew DA. Clinical outcome and bromodeoxyuridine derived proliferation indices in 100 colonic and rectal carcinomas. Eur J Surg Oncol 2002; 28:516–9PubMedCrossRefGoogle Scholar
  15. 15.
    Terry NHA, Meistrich ML, Roubein LD, et al. Cellular kinetics in rectal-cancer. Br J Cancer 1995; 72:435–41PubMedGoogle Scholar
  16. 16.
    Suwinski R, Taylor JMG, Withers HR. Rapid growth of microscopic rectal cancer as a determinant of response to preoperative radiation therapy. Int J Radiat Oncol 1998; 42:943–51CrossRefGoogle Scholar
  17. 17.
    Sebag-Montefiore D, Brown G, Rutten H, et al. An international phase II study of capecitabine, oxaliplatin, radiotherapy and excision (CORE) in patients with MRI-defined locally advanced rectal adenocarcinoma. Interim results. Eur J Cancer 2005; 3(Suppl):170Google Scholar
  18. 18.
    Steel GG, Peckham MJ. Exploitable mechanisms in combined radiotherapy-chemotherapy—concept of additivity. Int J Radiat Oncol 1979; 5:85–91Google Scholar
  19. 19.
    Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004; 351:1731–40PubMedCrossRefGoogle Scholar
  20. 20.
    Nagtegaal I, Gaspar C, Marijnen C, et al. Morphological changes in tumour type after radiotherapy are accompanied by changes in gene expression profile but not in clinical behaviour. J Pathol 2004; 204:183–92PubMedCrossRefGoogle Scholar
  21. 21.
    De Meerleer G, Pattyn P, Fortan L, et al. High-dose preoperative radiotherapy does not alter the strength of unilaterally irradiated colon anastomoses in rats. Int J Radiat Oncol 1999; 44:163–70CrossRefGoogle Scholar
  22. 22.
    El-Malt M, Ceelen W, De Meerleer G, et al. Influence of preoperative combined radiochemotherapy on surgical outcome and colonic anastomotic healing: experimental study in the rat. Int J Radiat Oncol 2001; 50:1073–8CrossRefGoogle Scholar
  23. 23.
    O’Leary DP, Fide CJ, Foy C, et al. Quality of life after low anterior resection with total mesorectal excision and temporary loop ileostomy for rectal carcinoma. Br J Surg 2001; 88:1216–20PubMedCrossRefGoogle Scholar
  24. 24.
    Gastinger I, Marusch F, Steinert R, et al. Protective defunctioning stoma in low anterior resection for rectal carcinoma. Br J Surg 2005; 92:1137–42PubMedCrossRefGoogle Scholar
  25. 25.
    Coucke PA, Sartorelli B, Cuttat JF, et al. The rationale to switch from postoperative hyperfractionated accelerated radiotherapy to preoperative hyperfractionated accelerated radiotherapy in rectal cancer. Int J Radiat Oncol 1995; 32:181–8Google Scholar
  26. 26.
    Voelter V, Stupp R, Matter M, et al. Preoperative hyperfractionated accelerated radiotherapy (HART) and concomitant CPT-11 in locally advanced rectal carcinoma: a phase I study. Int J Radiat Oncol 2003; 56:1288–94CrossRefGoogle Scholar
  27. 27.
    Bujko K, Nowacki MP, Nasierowska-Guttmejer A, et al. Sphincter preservation following preoperative radiotherapy for rectal cancer: report of a randomised trial comparing short-term radiotherapy vs conventionally fractionated radiochemotherapy. Radiother Oncol 2004; 72:15–24PubMedCrossRefGoogle Scholar
  28. 28.
    Weinstein GD, Rich TA, Shumate CR, et al. Preoperative infusional chemoradiation and surgery with or without an electron-beam intraoperative boost for advanced primary rectal cancer. Int J Radiat Oncol 1995; 32:197–204Google Scholar
  29. 29.
    Sun XN, Yang QC, Hu JB. Pre-operative radiochemotherapy of locally advanced rectal cancer. World J Gastroenterol 2003; 9:717–20PubMedGoogle Scholar
  30. 30.
    Crane CH, Skibber JM, Birnbaum EH, et al. The addition of continuous infusion 5-FU to preoperative radiation therapy increases tumor response, leading to increased sphincter preservation in locally advanced rectal cancer. Int J Radiat Oncol 2003; 57:84–9CrossRefGoogle Scholar
  31. 31.
    Bouliswassif S, Gerard A, Loygue J, et al. Final results of a randomized trial on the treatment of rectal cancer with preoperative radiotherapy alone or in combination with 5-fluorouracil, followed by radical surgery—trial of the European Organization on Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. Cancer 1984; 53:1811–8CrossRefGoogle Scholar
  32. 32.
    Gerard J, Conroy T, Bonnetain F, et al. Preoperative (Preop) radiotherapy (RT) plus FU/folinic acid (FA) in T3.4 rectal cancers: preliminary results of the FFCD 9203 randomized trial. Int JRadiat Oncol 2004; 60:S138CrossRefGoogle Scholar
  33. 33.
    Conroy T, Bonnetain F, Chapet O, et al. Preoperative (preop) radiotherapy (RT) + 5FU/folinic acid (FA) in T3,4 rectal cancers: preliminary results of the FFCD 9203 randomized trial. J Clin Oncol 2004; 22:276sGoogle Scholar
  34. 34.
    Bosset JF, Calais G, Mineur L, et al. Does the addition of chemotherapy (CT) to preoperative radiotherapy (preopRT) increase the pathological response in patients with resected rectal cancer? Report of the 22921 EORTC phase III trial. J Clin Oncol 2004; 22:246SGoogle Scholar
  35. 35.
    Bosset JF, Calais G, Mineur L, et al. Enhanced tumorocidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: preliminary results—EORTC 22921. J Clin Oncol 2005; 23:5620–7PubMedCrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2006

Authors and Affiliations

  • Wim Ceelen
    • 1
  • Tom Boterberg
    • 2
  • Piet Pattyn
    • 1
  • Marc van Eijkeren
    • 2
  • Jean-Marc Gillardin
    • 1
  • Pieter Demetter
    • 3
  • Peter Smeets
    • 4
  • Nancy Van Damme
    • 5
  • Els Monsaert
    • 5
  • Marc Peeters
    • 5
  1. 1.Department of Surgical OncologyUniversity HospitalGhentBelgium
  2. 2.Department of RadiotherapyUniversity HospitalGhentBelgium
  3. 3.Department of PathologyErasmus HospitalBrusselsBelgium
  4. 4.Department of RadiologyUniversity HospitalGhentBelgium
  5. 5.Department of HepatogastroenterologyUniversity HospitalGhentBelgium

Personalised recommendations